Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Women Clear all
Not listed Phase 1Phase 2 Interventional

Effect of Testosterone Treatment on Embryo Quality

NCT01662466
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions
Testosterone cream (0.5mg per gram), DHEA, Placebo
Drug · Dietary Supplement
Lead sponsor
Center for Human Reproduction
Other
Eligibility
38 Years to 44 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral capsule, Placebo oral capsule
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 18, 2026, 9:00 PM EDT
Terminated Not applicable Interventional

Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer

NCT00856453
View directory record Official record
Conditions
Depression, Fatigue, Ovarian Cancer
Interventions
Home yoga practice, yoga classes
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

NCT00226980
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Thalidomide, Capecitabine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2009 · Synced Sep 18, 2026, 9:00 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

NCT07773727
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
ARGX-121, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Miami, Florida • Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 18, 2026, 9:00 PM EDT
Completed No phase listed Observational

Chitosan Chewing Gum Study in Dialysis Patients

NCT01770470
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Chitosan
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873
View directory record Official record
Conditions
Obesity
Interventions
ERX1000, Placebo
Drug
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT05299554
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
16 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 18, 2026, 9:00 PM EDT
Not listed Not applicable Interventional

Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions

NCT02292056
View directory record Official record
Conditions
Mental Disorders, Contraception, Chemical Teratogen Exposure
Interventions
1-on-1 counseling
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

NCT01693029
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease (CKD)
Interventions
HX575 epoetin alfa, US-licensed epoetin alfa
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
52
States / cities
Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

NCT00590629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Niaspan
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

NCT01257841
View directory record Official record
Conditions
Healthy
Interventions
Leptin administration, Fasting
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

NCT04935294
View directory record Official record
Conditions
Healthy, Renal Dysfunction
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

NCT02166905
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis, Pharmacological Study, Poly ICLC
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 18, 2026, 9:00 PM EDT
Recruiting Phase 2 Interventional

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

NCT07516366
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Nephrectomy, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Not applicable Interventional

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

NCT06343129
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Dietary education program
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 18, 2026, 9:00 PM EDT
Recruiting Not applicable Interventional

Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)

NCT05849077
View directory record Official record
Conditions
Premature Infants, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Neurodevelopmental Outcomes
Interventions
Sat75, Sat50
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Minutes to 10 Minutes
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 18, 2026, 9:00 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships

NCT00601939
View directory record Official record
Conditions
Battered Women, Suicide, Attempted
Interventions
Psychoeducational intervention (PEI), Enhanced treatment as usual (ETAU)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

NCT03300557
View directory record Official record
Conditions
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Accuracy and Reliability of Fetal Heart Rate and Uterine Contraction Monitoring Method

NCT01280357
View directory record Official record
Conditions
Pregnancy; Habitual Aborter, Weeks of Gestation 37 or More
Interventions
Monica AN24 (K101081), Philips 50XM
Device
Lead sponsor
Monica Healthcare Ltd
Industry
Eligibility
15 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 18, 2026, 9:00 PM EDT
Completed Not applicable Interventional

The Measurement of Insulin Resistance in Peritoneal Dialysis Patients

NCT01119196
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Icodextrin dialysate
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Sep 18, 2026, 9:00 PM EDT
Terminated Phase 1Phase 2 Interventional

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

NCT00003086
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CAF regimen, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, ifosfamide, melphalan, paclitaxel, thiotepa, peripheral blood stem cell transplantation, samarium Sm 153 lexidronam pentasodium
Biological · Drug · Procedure + 1 more
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 18, 2026, 9:00 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

NCT06353269
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions
Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 18, 2026, 9:00 PM EDT